Clinical Trials Logo

Peripheral Arterial Disease clinical trials

View clinical trials related to Peripheral Arterial Disease.

Filter by:

NCT ID: NCT02169921 Completed - Clinical trials for Peripheral Arterial Disease

TurboHawk™ Japan Trial in Patients With PAD

Start date: June 2014
Phase: N/A
Study type: Interventional

The objective of this study is to evaluate the safety and effectiveness of the TurboHawk for the treatment of peripheral arterial disease (PAD) in the superficial femoral and/or the popliteal arteries with the Japanese population.

NCT ID: NCT02163863 Completed - Clinical trials for Peripheral Arterial Disease

BioMimics 3D Stent Clinical Investigation: The Mimics Study

Mimics
Start date: February 2010
Phase: N/A
Study type: Interventional

Primary purpose of the Mimics Study is to evaluate the safety and performance of the BioMimics 3D Stent System in the treatment of symptomatic SFA/proximal popliteal disease.

NCT ID: NCT02145845 Completed - Clinical trials for Peripheral Arterial Disease

Pilot Safety Study of Injectable SIS for Critical Limb Ischemia

CLIC
Start date: April 2014
Phase: N/A
Study type: Interventional

This study is intended to collect safety and effectiveness data on the Cook Injectable Small Intestinal Submucosa (SIS)

NCT ID: NCT02145065 Completed - Clinical trials for Peripheral Artery Disease

First-in-man Evaluation of a Novel, Microcrystalline Paclitaxel Coated Balloon for Treatment of Femoropopliteal Artery Disease (PAX-r)

PAX
Start date: September 2014
Phase: N/A
Study type: Interventional

The purpose of this pivotal, first in man study will be to evaluate safety and efficacy of the novel, microcrystalline paclitaxel coated balloon (mcPCB, PAK, Balton) in the treatment of femoropopliteal artery disease.

NCT ID: NCT02143102 Completed - Clinical trials for Peripheral Arterial Disease

Non-invasive Computer-Aided Phenotyping of Vasculopathy

Q-CAMP
Start date: July 2014
Phase:
Study type: Observational

The investigators use MRI and/or CT to evaluate the extent, as well as, the structure, composition, and functional aspects of atherosclerotic plaques in human carotid and femoral arteries in patients scheduled to undergo an endarterectomy of the aforementioned vascular beds as part of their routine clinical care.

NCT ID: NCT02137577 Completed - Clinical trials for Peripheral Artery Disease

AcoArt Ⅱ/ BTK China: Drug-eluting Balloon for Below-The-Knee Angioplasty Evaluation in China

Start date: May 2014
Phase: N/A
Study type: Interventional

The purpose of this study is to determine whether DEB is more effective than common PTA balloon using under in long-term vessel patency and inhibiting restenosis in the infrapopliteal artery.

NCT ID: NCT02135848 Completed - Clinical trials for Vascular Disease, Peripheral

3 Month PHI PAD PoM Study

Start date: October 15, 2010
Phase: Phase 2
Study type: Interventional

This is a multi-center, randomized, blinded, placebo controlled study to evaluate the safety of GSK1278863 and its acute and short-term (e.g. 14d) effects on calf muscle endurance and walking ability in subjects with PAD and symptomatic claudication.

NCT ID: NCT02129634 Completed - Clinical trials for Peripheral Arterial Disease

Singapore INfra-Genicular Angioplasty With PAclitaxel-eluting Balloon for Critical Limb Ischaemia (SINGA-PACLI) Trial

SINGA-PACLI
Start date: December 27, 2013
Phase: N/A
Study type: Interventional

Background - In patients with critical limb ischaemia (CLI), the infragenicular arteries are often involved. Without revascularisation, amputation often is imperative. There is a high technical success rate of endovascular revascularisation of infragenicular arteries with percutaneous transluminal angioplasty (PTA), but mid- and long-term results are disappointing as restenosis frequently occurs. Drug-eluting balloon (DEB) PTA has been shown to improve patency rates after PTA of coronary arteries. Aim - To study the results of DEB-PTA compared to conventional balloon CB-PTA for the treatment of infragenicular lesions in patients with CLI. - To evaluate cost-effectiveness of DEB-PTA versus CB-PTA in patients with critical limb ischemia (CLI) by quantifying the incremental cost-effectiveness ratio (ICER). Hypothesis - DEB PTA results in improved patency rates compared to CB-PTA for treatment of infragenicular arterial lesions in patients with CLI. - DEB-PTA is a cost-effective strategy in patients with CLI compared with CB-PTA. Methodology Multi-center, prospective, randomised parallel-group trial. Patients are eligible for enrolment if they have CLI and at least one infragenicular lesion with a maximal total lesion length of 20cm. Randomisation will be performed on a 1:1 ratio to either DEB-PTA or CB-PTA. Patients will be assessed prior and directly after the intervention, at 3, 6 and 12 months by Rutherford classification, ankle-brachial index, toe pressure and adverse events. Duplex will be performed at 3 months. Angiography will be performed before and directly after PTA and at 6 months. Primary end-point will be primary patency of the treated lesions at 6 months on angiography (defined as <50% stenosis, without re-intervention in the interim). Secondary end-points are limb salvage at 3, 6 and 12 months, primary patency of the treated lesion on Duplex at 3 months (defined as patency of the treated artery with peak systolic velocity (PSV) ≤2.0 m/sec), Rutherford classification, minor and major amputation, infrapopliteal endovascular re-intervention, patency of treated femoropopliteal sites (if applicable), infrapopliteal surgical bypass, peri-procedural complications and death at 3, 6 and 12 months. A cost-effectiveness analysis (CEA) from a societal perspective will be performed in parallel with the randomized clinical trial with a 12-month time horizon.

NCT ID: NCT02129127 Completed - Clinical trials for Peripheral Vascular Disease

Drug-Coated Chocolate PTA Balloon in Patients With Peripheral Arterial Disease - The ENDURE Trial

ENDURE
Start date: March 2014
Phase: N/A
Study type: Interventional

This first-in-man study is to evaluate the Drug-Coated Chocolate (DCC) Balloon for percutaneous arterial angioplasty in patients with symptomatic peripheral arterial disease. The study focuses on acute device performance and peri-procedural safety and also seeks to further characterize the performance of the device.

NCT ID: NCT02126982 Completed - Clinical trials for Coronary Artery Disease

Salts of Clopidogrel: Investigation to ENsure Clinical Equivalence

SCIENCE
Start date: October 2012
Phase:
Study type: Observational

Clopidogrel besylate (CB) is not differentiated relative to the orignal clopidogrel hydrogen sulfate (CHS) in the pharmacokinetics and in antiplatelet potency in healthy volunteers. In addition,CB exhibits similar pharmacodynamic properties compared to CHS in patients with a history of acute coronary syndrome (ACS) and in patients with ACS undergoing percutaneous coronary intervention (PCI). However, there is a lack of data on the clinical efficacy and safety of this salt to the original salt in patients with cardiovascular disease. The aim of this study is to investigate the clinical efficacy and safety of CB in relation to that of CHS in patients eligible to receive clopidogrel.